EXPLEOSOL Stock Overview
Primarily provides software validation and verification services to the banking, financial services, and insurance industries worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 2/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for EXPLEOSOL from our risk checks.
Expleo Solutions Limited Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ₹1,308.50 |
| 52 Week High | ₹1,523.65 |
| 52 Week Low | ₹1,145.90 |
| Beta | 0.73 |
| 11 Month Change | 2.00% |
| 3 Month Change | -0.58% |
| 1 Year Change | 0.14% |
| 33 Year Change | -4.44% |
| 5 Year Change | 380.54% |
| Change since IPO | 695.92% |
Recent News & Updates
Recent updates
Expleo Solutions Limited's (NSE:EXPLEOSOL) CEO Compensation Is Looking A Bit Stretched At The Moment
Aug 24
When Should You Buy Expleo Solutions Limited (NSE:EXPLEOSOL)?
Jun 21Investors Could Be Concerned With Expleo Solutions' (NSE:EXPLEOSOL) Returns On Capital
Mar 15The Returns On Capital At Expleo Solutions (NSE:EXPLEOSOL) Don't Inspire Confidence
Sep 15Increases to Expleo Solutions Limited's (NSE:EXPLEOSOL) CEO Compensation Might Cool off for now
Aug 19Calculating The Fair Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)
Jul 14Many Would Be Envious Of Expleo Solutions' (NSE:EXPLEOSOL) Excellent Returns On Capital
May 05A Look At The Fair Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)
Mar 15Expleo Solutions Limited's (NSE:EXPLEOSOL) Stock Been Rising: Are Strong Financials Guiding The Market?
Feb 15
Expleo Solutions (NSE:EXPLEOSOL) Knows How to Allocate Capital
Jan 24Introducing Expleo Solutions (NSE:EXPLEOSOL), A Stock That Climbed 76% In The Last Year
Jan 04A Look At The Intrinsic Value Of Expleo Solutions Limited (NSE:EXPLEOSOL)
Dec 14Is There More To The Story Than Expleo Solutions's (NSE:EXPLEOSOL) Earnings Growth?
Nov 26Shareholder Returns
| EXPLEOSOL | IN IT | IN Market | |
|---|---|---|---|
| 7D | 7.8% | -1.9% | 0.3% |
| 1Y | 0.1% | 23.2% | 27.3% |
Return vs Industry: EXPLEOSOL underperformed the Indian IT industry which returned 23.9% over the past year.
Return vs Market: EXPLEOSOL underperformed the Indian Market which returned 27.2% over the past year.
Price Volatility
| EXPLEOSOL volatility | |
|---|---|
| EXPLEOSOL Average Weekly Movement | 3.8% |
| IT Industry Average Movement | 6.3% |
| Market Average Movement | 6.1% |
| 10% most volatile stocks in IN Market | 9.2% |
| 10% least volatile stocks in IN Market | 4.0% |
Stable Share Price: EXPLEOSOL has not had significant price volatility in the past 3 months compared to the Indian market.
Volatility Over Time: EXPLEOSOL's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1998 | 4,291 | Phani Tangirala | investors.expleo.com |
Expleo Solutions Limited, together with its subsidiaries, primarily provides software validation and verification services to the banking, financial services, and insurance industries worldwide. It offers computer programming, consultancy and related activities, quality management, software development, software testing, software development, digital transformation, product and process engineering, quality and testing, and customer support and maintenance services. The company was formerly known as SQS India BFSI Limited and changed its name to Expleo Solutions Limited in April 2019.
Expleo Solutions Limited Fundamentals Summary
| EXPLEOSOL fundamental statistics | |
|---|---|
| Market cap | ₹20.31b |
| Earnings (TTM) | ₹1.09b |
| Revenue (TTM) | ₹10.28b |
18.6x
P/E Ratio2.0x
P/S RatioIs EXPLEOSOL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| EXPLEOSOL income statement (TTM) | |
|---|---|
| Revenue | ₹10.28b |
| Cost of Revenue | ₹6.17b |
| Gross Profit | ₹4.11b |
| Other Expenses | ₹3.01b |
| Earnings | ₹1.09b |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 14, 2025
| Earnings per share (EPS) | 70.31 |
| Gross Margin | 39.95% |
| Net Profit Margin | 10.62% |
| Debt/Equity Ratio | 0% |
How did EXPLEOSOL perform over the long term?
See historical performance and comparison